| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $25,716,890 | 5 | 100 |
Sells | $0 | 0 | 0 |
| Flynn James E | * Director by Deputization | 1 | $25M | 0 | $0 | $25M |
| Hamilton Thomas Edward | director | 2 | $666,890 | 0 | $0 | $666,890 |
| SHERMAN JEFFREY W | director | 1 | $25,000 | 0 | $0 | $25,000 |
| THOMAS FRANK E | director | 1 | $25,000 | 0 | $0 | $25,000 |
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Over the last 12 months, insiders at Larimar Therapeutics, Inc. have bought $25.72M and sold $0 worth of Larimar Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Larimar Therapeutics, Inc. have bought $26M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Flynn James E (* Director by Deputization) — $25M. Hamilton Thomas Edward (director) — $666,890. SHERMAN JEFFREY W (director) — $25,000.
The last purchase of 50,000 shares for transaction amount of $166,890 was made by Hamilton Thomas Edward (director) on 2026‑07‑06.
| 2026-07-06 | Hamilton Thomas Edward | director | 50,000 0.0593% | $3.34 | $166,890 | +16.11% | ||
| 2026-02-27 | Flynn James E | * Director by Deputization | 5M 5.5007% | $5.00 | $25M | -27.12% | ||
| 2026-02-27 | Hamilton Thomas Edward | director | 100,000 0.11% | $5.00 | $500,000 | -27.12% | ||
| 2026-02-27 | THOMAS FRANK E | director | 5,000 0.0055% | $5.00 | $25,000 | -27.12% | ||
| 2026-02-27 | SHERMAN JEFFREY W | director | 5,000 0.0055% | $5.00 | $25,000 | -27.12% | ||
| 2025-07-31 | Flynn James E | * Director by Deputization | 9.38M 13.5418% | $3.20 | $30M | +10.69% | ||
| 2024-02-16 | Flynn James E | * Director by Deputization | 4.29M 6.6831% | $8.74 | $37.5M | -41.94% | ||
| 2024-02-16 | Hamilton Thomas Edward | director | 57,208 0.0891% | $8.74 | $499,998 | -41.94% | ||
| 2024-02-14 | THOMAS FRANK E | director | 2,000 0.0064% | $11.00 | $22,000 | -37.88% | ||
| 2023-12-07 | Shankar Gopi | Chief Development Officer | 5,000 0.0119% | $3.73 | $18,662 | +105.22% | ||
| 2023-05-17 | BEN-MAIMON CAROLE | President and CEO | 5,000 0.0114% | $3.71 | $18,525 | +8.67% | ||
| 2023-05-17 | Celano Michael | Chief Financial Officer | 5,000 0.0115% | $3.73 | $18,632 | +8.67% | ||
| 2023-05-17 | Truitt Joseph | director | 2,750 0.0063% | $3.73 | $10,258 | +8.67% | ||
| 2022-09-16 | Flynn James E | 11.11M 49.2054% | $3.15 | $35M | +21.72% | |||
| 2022-09-16 | Hamilton Thomas Edward | director | 317,460 1.4059% | $3.15 | $999,999 | +21.72% | ||
| 2022-09-16 | BEN-MAIMON CAROLE | President and CEO | 31,746 0.1406% | $3.15 | $100,000 | +21.72% | ||
| 2022-09-16 | Celano Michael | Chief Financial Officer | 31,746 0.1406% | $3.15 | $100,000 | +21.72% | ||
| 2021-06-30 | Flynn James E | 685,710 3.341% | $8.75 | $6M | -2.39% | |||
| 2021-06-30 | Hamilton Thomas Edward | director | 56,710 0.2763% | $8.75 | $496,213 | -2.39% | ||
| 2018-06-28 | Sale | Hughes Thomas E. | See Remarks | 32,000 0.1034% | $10.00 | $320,000 | -47.50% |
| Flynn James E | * Director by Deputization | 10622957 10.2259% | $26.98M | 9 | 1 | <0.0001% |
| Hamilton Thomas Edward | director | 714798 0.6881% | $1.82M | 5 | 0 | <0.0001% |
| THOMAS FRANK E | director | 7000 0.0067% | $17,780.00 | 2 | 0 | <0.0001% |
| SHERMAN JEFFREY W | director | 5000 0.0048% | $12,700.00 | 1 | 0 | |
| BEN-MAIMON CAROLE | President and CEO | 266829 0.2569% | $677,745.66 | 2 | 0 | +15.2% |
| Hughes Thomas E. | See Remarks | 125247 0.1206% | $318,127.38 | 2 | 4 | +20.01% |
| Celano Michael | Chief Financial Officer | 112746 0.1085% | $286,374.84 | 2 | 0 | +15.2% |
| Heller Frances K | director | 47961 0.0462% | $121,820.94 | 4 | 0 | +29.04% |
| KIM DENNIS D | Chief Medical Officer | 21443 0.0206% | $54,465.22 | 3 | 3 | +11.81% |
| Allen Patricia L | Chief Financial Officer | 19793 0.0191% | $50,274.22 | 2 | 0 | +14.98% |
| Shankar Gopi | Chief Development Officer | 5000 0.0048% | $12,700.00 | 1 | 0 | +105.22% |
| Truitt Joseph | director | 2750 0.0026% | $6,985.00 | 1 | 0 | +8.67% |
| Secor Alicia | Chief Commercial Officer | 0 0% | $0 | 1 | 1 | +21.04% |
$60,836,085 | 69 | 0.45% | $255.44M | |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
Larimar Therapeutics, Inc. (LRMR) | $109,019,806 | 28 | 7.37% | $263.86M |
$3,668,031 | 23 | 2.05% | $243.03M |
| Increased Positions | 69 | +46.94% | 6M | +7.04% |
| Decreased Positions | 61 | -41.5% | 18M | -21.61% |
| New Positions | 23 | New | 1M | New |
| Sold Out Positions | 19 | Sold Out | 14M | Sold Out |
| Total Postitions | 155 | +5.44% | 73M | -14.57% |
| Deerfield Management Company, L.P. | $106,206.00 | 35.59% | 30.61M | +9M | +44.16% | 2025-09-30 |
| Ra Capital Management, L.P. | $20,977.00 | 7.03% | 6.05M | 0 | 0% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $20,310.00 | 6.81% | 5.85M | +925,000 | +18.77% | 2025-09-30 |
| Millennium Management Llc | $16,992.00 | 5.69% | 4.9M | +1M | +33.97% | 2025-09-30 |
| Opaleye Management Inc. | $12,911.00 | 4.33% | 3.72M | -389,133 | -9.47% | 2025-09-30 |
| Blackrock, Inc. | $11,587.00 | 3.88% | 3.34M | +299,212 | +9.84% | 2025-09-30 |
| Rtw Investments, Lp | $10,844.00 | 3.63% | 3.13M | +3M | New | 2025-09-30 |
| Vanguard Group Inc | $10,715.00 | 3.59% | 3.09M | +945,809 | +44.16% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $6,593.00 | 2.21% | 1.9M | +2M | New | 2025-09-30 |
| Alyeska Investment Group, L.P. | $6,548.00 | 2.19% | 1.89M | -188,713 | -9.09% | 2025-09-30 |